American Journal of Tropical Medicine and Hygiene · 2011 · 32 citations · 9 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyChemotherapyAntimicrobial DosingChemotherapy Drug AdministrationLiposomal FormulationsAntileishmanial TreatmentClinical Outcome MeasurementLeishmaniasis PathogenesisOptimal Dose SelectionTotal DoseTreatment Of Leishmaniasis
Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).
9
Cutaneous leishmaniasis – Authors' reply
Richard Reithinger, Jean‐Claude Dujardin, Hechmi Louzir et al. · The Lancet Infectious Diseases · 2008 · 361 citations
Shyam Sundar, Prabhat Kumar Sinha, Madhukar Rai et al. · The Lancet · 2011 · 335 citations